US HB6963 | 2021-2022 | 117th Congress
Status
Spectrum: Partisan Bill (Democrat 2-0)
Status: Introduced on March 7 2022 - 25% progression, died in committee
Action: 2022-03-08 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on March 7 2022 - 25% progression, died in committee
Action: 2022-03-08 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Federal Food, Drug, and Cosmetic Act to strengthen requirements for postapproval studies for drugs approved using accelerated approval, and for other purposes.
Title
Accelerated Approval Integrity Act of 2022
Sponsors
Rep. Frank Pallone [D-NJ] | Rep. Carolyn Maloney [D-NY] |
History
Date | Chamber | Action |
---|---|---|
2022-03-08 | House | Referred to the Subcommittee on Health. |
2022-03-07 | House | Referred to the House Committee on Energy and Commerce. |
2022-03-07 | House | Introduced in House |
Subjects
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/117th-congress/house-bill/6963/all-info |
Text | https://www.congress.gov/117/bills/hr6963/BILLS-117hr6963ih.pdf |